In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until eventually disease progression or the participants are unable to tolerate the study drugs. - "Our study disclosed the critical role with the KLF16/MYC regulatory axis in https://helenz444teo6.kylieblog.com/profile